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A major goal of drug abuse research is to identify and understand drug-induced changes in brain function that are common to
many or all drugs of abuse. As these may underlie drug dependence and addiction, the purpose of the present study was to
examine if different drugs of abuse effect changes in gene expression that converge in common molecular pathways.
Microarray analysis was employed to assay brain gene expression in postmortem anterior prefrontal cortex (aPFC) from 42
human cocaine, cannabis and/or phencyclidine abuse cases and 30 control cases, which were characterized by toxicology and
drug abuse history. Common transcriptional changes were demonstrated for a majority of drug abuse cases (N=34),
representing a number of consistently changed functional classes: Calmodulin-related transcripts (CALM1, CALM2, CAMK2B)
were decreased, while transcripts related to cholesterol biosynthesis and trafficking (FDFT1, APOL2, SCARB1), and Golgi/
endoplasmic reticulum (ER) functions (SEMA3B, GCC1) were all increased. Quantitative PCR validated decreases in calmodulin 2
(CALM2) mRNA and increases in apolipoprotein L, 2 (APOL2) and semaphorin 3B (SEMA3B) mRNA for individual cases. A
comparison between control cases with and without cardiovascular disease and elevated body mass index indicated that these
changes were not due to general cellular and metabolic stress, but appeared specific to the use of drugs. Therefore, humans
who abused cocaine, cannabis and/or phencyclidine share a decrease in transcription of calmodulin-related genes and
increased transcription related to lipid/cholesterol and Golgi/ER function. These changes represent common molecular
features of drug abuse, which may underlie changes in synaptic function and plasticity that could have important ramifications
for decision-making capabilities in drug abusers.
Citation: Lehrmann E, Colantuoni C, Deep-Soboslay A, Becker KG, Lowe R, et al (2006) Transcriptional Changes Common to Human Cocaine, Cannabis
and Phencyclidine Abuse. PLoS ONE 1(1): e114. doi:10.1371/journal.pone.0000114
INTRODUCTION
While human drug abusers exhibit specific preferences in their
individual drugs-of-choice, polysubstance abuse is the rule, not the
exception [1]. Animal studies have suggested that although different
drugs of abuse have unique and specific mechanisms of action, the
same molecular pathways may be involved in mediating common
functional effects of multiple drugs of abuse [2]. These molecular
pathways may therefore reflect common changes in brain function
that promote continued drug use and compulsive drug-seeking
behavior, irrespective of which particular drugs are abused.
Multiple brain regions are involved in the establishment and
maintenance of addictive behavior. The prefrontal cortical
regulation of cognitive and emotional processes is changed by
drug abuse, such that inhibitory control of these processes is
deficient and drug use is reinforced [3,4]. The aPFC, defined as
the anterior pole of Brodmann Area 10 (BA10), contains fewer
cells, but with a higher spine density and length, than any other
cortical region [5]. It is reciprocally connected to the prefrontal
anterior temporal and cingulate cortices and has been suggested to
serve an important integrative role in the pursuit of behavioral
goals [6]. Concurrent activation of the aPFC and the orbitofrontal
cortex has been demonstrated following administration of cocaine
to cocaine-abusing individuals [7]. As a consequence, altered
function of the aPFC could have important ramifications for
decision-making capability in drug abusers.
Microarray analysis has been used to identify transcriptional
changes in human neuropsychiatric disorders, including schizo-
phrenia, depression and bipolar disorder [8–12] and in association
with specific abused drugs [13–16]. Missing from these studies,
however, are microarray analyses of the general transcriptional
features of drug abuse per se. To address this topic, we performed
a microarray study of human postmortem aPFC from 30 control
cases and 42 drug abuse cases with varied drug abuse histories. A
series of cases with cocaine, cannabis and/or phencyclidine as the
primary drugs of abuse were examined for common patterns of
regulation of gene expression that would represent identifiable
biological functions. By classifying consistently regulated tran-
scripts into biologically-relevant functional groups, we identified
decreased expression of transcripts involved in calmodulin-related
signaling and increased expression of transcripts involved in lipid/
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METHODS
Source and selection of cases
A series of 646 consecutive cases from the brain repository at the
Clinical Brain Disorders Branch (NIMH IRP) were reviewed for
evidence of drug abuse by either history or toxicology. Of the 138
cases identified, 50 cases were identified by a history of drug abuse,
25 cases by a positive toxicology test, and 63 cases were identified
by both measures. Cases were excluded on the basis of co-morbid
neurological or major psychiatric disorders, abnormal microscopic
or macroscopic neuropathology, poor RNA quality, postmortem
intervals (PMI) .72 hrs, or brain pH,6.0. A subset of 42 cases
was retained, for which clinical case histories were compiled from
chart records, medical examiner’s files and structured interviews
with next-of-kin to the extent possible. Controls (N=30) were
similarly selected from a well-characterized control cohort [17].
To limit the impact of confounds from any one control, each drug
abuse case was matched to four controls that both individually and
on average were the best matches for brain pH, PMI, age, gender,
ethnicity and smoking history. Group mean demographic data are
provided for drug abuse and control cases in Table 1, which
demonstrate that brain pH, PMI, age and gender did not differ
significantly between drug abusers and their individual control
tetrads. Demographic data for individual cases are provided in
Table S1.
Toxicological evaluation
General toxicological information on drugs of abuse present at
death was obtained from the medical examiner’s office, and
supplemented with additional toxicological testing of blood or brain
to validate and extend the scope of drugs initially tested (National
Medical Services, Willow Grove, PA). Gas chromatography-mass
spectrometry (GC-MS) was employed to examine cerebellar tissue
from all 72 cases for the presence of cocaine, amphetamine,
phencyclidine, opioids and their metabolites [18]. In addition to this
generaltoxicologicalevaluation,hairtoxicologywasemployedfor31
drugabusecasesand10controlcases,whichprovidedaretrospective
evaluation of exposure to cocaine, phencyclidine, amphetamines,
opioids and cannabinoids (Psychemedics Corporation, Culver City,
CA) in the months prior to death. General and hair toxicological
findings are summarized in Table 2.
Microarray experiments
Microarray experiments were essentially carried out as previously
described [14]. Briefly, RNA was extracted from pulverized gray
matter from BA10 (dorsal aspect, frontal pole) using Trizol reagent
(Invitrogen, Carlsbad, CA). The quality and quantity of sample
RNA was evaluated by Bioanalyzer electrophoresis (Agilent, Palo
Alto, CA). Eight mg total RNA from each sample was reverse
transcribed into
33P-labeled individual cDNA samples, and
divided for duplicate hybridizations to Mammalian Gene
Collection (MGC) arrays containing 9216 cDNA clones from
the MGC clone set [19]. The arrays were exposed to a low-energy
phosphor screen (Molecular Dynamics, Sunnyvale, CA) for 5 days,
the screen scanned (Phosphorimager 860, Molecular Dynamics),
and pixel intensities quantified using ImageQuant (Molecular
Dynamics).
Z-score transformation
The microarray data sets were analyzed using the z-score
transformation normalization method [20], in which log-trans-
formed and normalized hybridization intensity values provided the
basis for p-value-based significance calculations by a z-test. Two-
tailed p-values were used to identify transcripts with decreased or
increased expression, respectively. Individual z-ratio data repre-
sent a normalized ratio between experimental and control cases.
Hierarchical clustering
Hierarchical clustering of z-ratio data using Genesis software [21]
was used to assess the overall relatedness of the global
transcriptional changes for all drug abuse cases.
Groups defined by global transcriptional profiles:
selection and GAP criteria
Two-tailed p-values for individual transcripts were averaged within
each of the three groups, and formed the basis for selection of
transcripts by group average p-value (GAP) criteria. Transcripts for
which one (or more) GAP was #0.01 (or $0.99) were included to
select transcripts strongly decreased (or increased, respectively) in
individual groups, while transcripts where one (or more) GAP
#0.05 (or $0.95) and one (or more) GAP #0.10 (or $0.90) were
selected to include transcripts common to any two (or more)
groups. Cases DA 17–18 were omitted from Group I GAP for this
calculation only as they represented an intermediate between
Group I and Group II (Fig. 1).
Groups defined by toxicology: selection and GAP
criteria
General toxicology (all toxicological data except hair testing)
detected drugs of abuse in 26 Group I–II cases. Two cases with
unknown drug abuse histories and negative or unavailable hair
toxicological tests were excluded. The remaining 24 cases were
divided among 12 cocaine (COC+), 9 cannabis (THC+), and 3
phencyclidine (PCP+) cases. The probability of decreased or
increased expression were selected as GAP #0.10 and $0.90,
respectively.
Table 1. Summary of the demographic information for drug
abuse (42) and control cases (30).
......................................................................
Factor Drug abuse cases Control cases p-value
Brain pH 6.7260.24 6.6860.19 p=0.45*
PMI 25.05613.72 24.8567.74 p=0.93*
Age 31.05611.09 31.9068.17 p=0.69*
Gender 16.7% F, 83.3% M 13.7% F, 86.3% M p=0.13**
Nicotine use 38.1% NS, 61.9% S 51.8% NS, 48.2% S p=0.12**
Ethnicity 0% A 1.2% A p=0.0019**
85.7% AA 60.7% AA (AA vs. others)
9.5% CAUC 28.6% CAUC
4.8% HISP 9.5% HISP
Each drug abuse case was matched to four control cases (Supporting
Information, Table 4) by brain pH, postmortem interval (PMI, hours), age (years),
gender (F – female, M – male), nicotine use (NS – non-smoker, S - smoker) and
ethnicity (A - Asian, AA – African-American, CAUC – Caucasian, HISP – Hispanic).
Means shown are derived from the averages of the four controls matched to
each individual drug abuse case. P-values were derived using either a *t-test
(two-tailed) or **Fisher’s Exact Test (two-tailed). For the latter test, data for each
control was entered corresponding to the total number of times the control
was used.
doi:10.1371/journal.pone.0000114.t001
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e114To select transcripts which were similarly changed in the groups
defined by toxicology described above and also in all 34 Group I–
II cases, transcripts with average p-values #0.10 (or $0.90) for all
cases were selected if (i) at least 30 cases (<90%) had GAP scores
#0.10 (or $0.90), and (ii) GAP #0.06 (or $0.94) for two (or three)
of the groups defined by general toxicology.
Specificity of the findings
Ethnicity GAP scores for six African-American male (AAM)
drug abuse cases (DA3, 4, 5, 14, 20, 26) which each were matched
exclusively to four AAM control cases were employed to examine
if differences in ethnicity played a significant factor in transcript
selection. AAM GAP scores are included in Table 3.
Cardiovascular disease Each of six overweight-obese
controls with cardiovascular disease (CTR 5, 7, 10, 11, 14, 26)
were compared to the best-matched three cases from a group of six
normal-overweight control cases with no history of cardiovascular
disease (CTR 12, 23, 27, 30, 31, 32), as indicated in Table S1.
Microarrays were processed at the same time for these and the
drug abuse cases. GAP scores are included for transcripts selected
for the drug abuse cases (Table 3, Table S2).
Annotation and nomenclature
Data were annotated using Source BatchSearch (http://genome-
www5.stanford.edu/cgi-bin/source//sourceBatchSearch), and
EntrezGene cross-database search (http://www.ncbi.nlm.nih.
Figure 1. Hierarchical clustering identified three main groups of drug abuse cases.
Hierarchical clustering of individual transcriptional profiles from comparisons of drug abuse cases and their individual four best-matched controls
identified three main groups of drug abusers: Group I (DA1–18), Group II (DA19–34) and Group III (DA35–42). A summary of toxicology and drug
abuse history for each case in the clustering dendrogram indicated cocaine use in a majority of cases, while presence of alcohol in Group I, and
opioids and phencyclidine in Group II might underlie differences in Group I and II individuals. Group III cases differed markedly from other cases,
which may be related to the absence or low levels of abused drug in most cases, a history of alcohol dependence, or to underlying medical
conditions.
Insufficient specimen for quantitative analysis of a positive hair test screening is indicated by a parenthesis around the substance name, units are ng/
mg, except for cTHC (pg/mg).
Abbreviations: 6AM – 6-acetyl morphine, AEME – anhydroecgonine methyl ester, BE - benzoylecgonine, CE – cocaethylene, COC – cocaine, COD -
codeine, cTHC – 11-nor-9-carboxy-tetrahydrocannabinol, EEE – ecgonine ethyl ester, EME – ecgonine methyl ester, EtOH – alcohol, g% - g/dL, MDMA
– N-Methyl-3,4-methylenedioxyamphetamine (Ecstasy), MOR – morphine, MTD – methadone, N/A – not available, OXYC – oxycodone, PCP –
phencyclidine, THC – delta-9-tetrahydrocannabinol.
doi:10.1371/journal.pone.0000114.g001
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PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e114Table 3. Significantly regulated transcripts identify three functional groups as shared across cocaine, cannabis and phencyclidine
abuse cases.
..................................................................................................................................................
EG SYMBOL ACCESSION LOCALIZATION AND FUNCTION GAPs: ALL COC+ THC+ PCP+ AAM CVDC
Calmodulin-related signaling
S100A16 BC019099 Calcium-binding protein 0.02 0.05 0.01 0.00 0.01 0.65
THTPA BC002984 Phosphatase, cAMP biosynthesis, AC activity 0.05 0.05 0.03 0.01 0.05 0.37
CAMK2B BC019070 Synaptic function and plasticity, calmodulin-modulated 0.02 0.03 0.01 0.00 0.00 0.55
CALM1 BC000454 Synaptic function and plasticity 0.06 0.01 0.17 0.04 0.00 0.45
CALM2 BC018677 Synaptic function and plasticity 0.04 0.00 0.13 0.01 0.00 0.43
CALM2 BC017385 Synaptic function and plasticity 0.05 0.03 0.13 0.01 0.00 0.47
Golgi/ER-related transcripts
AAK1 BC002695 Golgi/PM, CC AP2-associated kinase 0.93 1.00 0.86 0.98 0.99 0.32
AP1M2 BC005021 Golgi/PM, clathrin-coat (CC) adaptor protein 1 (AP1) 0.95 1.00 0.86 0.97 0.99 0.48
AP2A1 BC014214 Golgi/PM, CC AP2 0.96 0.95 0.96 0.97 0.95 0.36
AP4B1 BC014146 Golgi/PM, CC AP4 0.96 0.96 0.94 0.94 0.97 0.35
FLOT1 BC001146 Lipid raft/caveola-associated, endocytosis (non-CC) 0.04 0.03 0.10 0.00 0.01 0.37
RIMBP2 BC007632 Golgi, synaptic active zone, Rab3-IM-BP 0.04 0.01 0.13 0.00 0.01 0.55
RAB9A BC017265 Late endosome/lysosome, GTPase, vesicular trafficking 0.04 0.00 0.11 0.01 0.00 0.38
ASGR2 BC017251 Vesicular transport, Galact-term glycoproteins (lysosome) 0.02 0.01 0.03 0.02 0.01 0.65
ARL6IP4 BC015569 Nuclear, ARL6 GTP-binding IP, vesicular trafficking 0.03 0.02 0.06 0.00 0.00 0.61
NCLN BC019091 ER, TGFbeta superfamily signal transduction 0.08 0.10 0.01 0.02 0.22* 0.62
YIPF5 BC007829 Golgi/ER, Rab GTPase 0.94 0.95 0.94 0.99 0.96 0.30
GCC1 BC014100 Golgi (TGN) 0.96 0.95 0.95 0.98 0.93 0.42
COG4 BC013347 Golgi, retention and retrieval of Golgi proteins 0.93 1.00 0.81 0.98 1.00 0.47
COPZ1 BC002849 ER-Golgi transport, non-CC vesicle coat 0.95 1.00 0.85 0.98 1.00 0.45
CTSD BC016320 Lysosome, aspartyl protease 0.95 1.00 0.86 0.99 0.99 0.32
DPP7 BC011907 Lysosome, peptidase 0.95 1.00 0.86 1.00 1.00 0.41
CPVL BC016838 ER, peptidase 0.94 0.99 0.84 0.99 1.00 0.28
LEPREL1 BC005029 ER/Golgi, protein metabolism 0.94 0.95 0.86 0.97 0.97 0.54
SEMA3B BC013975 ER, growth cone guidance 0.95 0.99 0.87 0.97 0.99 0.34
CRMP1 BC007898 Semaphorin signal transduction pathway 0.91 0.99 0.71 0.94 0.99 0.31
VPS37C BC005805 Endosome, sorting ubiquinated transmembrane proteins 0.92 1.00 0.84 0.97 1.00 0.50
Lipid/cholesterol metabolism
APOL1 BC017331 HDL complex, cholesterol trafficking, secreted 0.03 0.00 0.09 0.02 0.01 0.65
APOL2 BC004395 HDL complex, cholesterol trafficking, cytoplasmic 0.97 0.99 0.91 0.94 0.98 0.30
SCARB1 NM_005505 HDL receptor 0.93 0.99 0.83 0.99 0.99 0.35
FDFT1 BC003573 ER, first step in cholesterol biosynthesis 0.92 1.00 0.83 0.99 1.00 0.47
PRKAB1 BC001823 Cell energy homeostasis, fatty acid biosynthesis 0.91 0.99 0.83 0.98 0.30** 0.50
LASS4 BC009828 ER, Ceramide synthesis 0.95 0.98 0.90 0.98 0.92 0.61
PTGES BC018201 Prostaglandin metabolism 0.96 0.96 0.94 0.98 0.91 0.34
ZDHHC1 BC021908 Palmitoyl transferase 0.98 0.98 0.96 0.98 0.96 0.32
ZDHHC8 BC009442 Palmitoyl transferase 0.93 0.99 0.83 1.00 0.89 0.49
PHLDB1 BC013031 PtdIns(3,4,5)P(3) binding, postsynaptic membrane 0.95 0.99 0.88 0.97 1.00 0.28
PXMP4 BC001147 Peroxisomal membrane protein, lipid metabolism 0.94 0.95 0.97 0.96 0.96 0.34
ECHDC1 BC003549 Peroxisomal oxidation of fatty acids 0.06 0.04 0.14 0.00 0.01 0.51
Thirty-nine significantly regulated transcripts belonged to three distinct functional groups: calmodulin-related signaling, Golgi/ER-related transcripts and lipid/
cholesterol metabolism. Group average p-values (GAPs, two-tailed z-test) are indicated for all 34 drug abuse cases (ALL), and for the three main groups of cases sorted
according to the drugs present at the time of death: cocaine (COC+, N=12), cannabis (THC+, N=9) and phencyclidine (PCP+, N=3). While factors such as brain pH,
postmortem interval, gender or smoking history were all well-matched, ethnicity was the only demographic variable that differed between groups (Table 1). To address
this issue, we examined only the six African-American male (AAM) drug abuse cases (18% of all drug abuse cases) that had been individually matched to four AAM
controls. Of the 39 transcripts that were significantly regulated (ALL and COC+,T H C + and/or PCP+ columns), 37 remained similarly regulated for the AAM group. There
were only two transcripts, NCLN (*) and PRKAB1 (**) for which the results were different for the AAM subgroup (see text). Therefore, as a factor in matching, ethnicity
had little effect on the identification of significantly regulated transcripts. Controls with cardiovascular disease (CVDC) and elevated body mass index (Table S1) did not
demonstrate changes in gene expression which were similar to those of the drug abuse cases. Table S2 contains the full list of transcripts. Gene symbols were annotated
using GenBank Accession numbers and EntrezGene.
doi:10.1371/journal.pone.0000114.t003
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e114gov/gquery/gquery.fcgi). Gene names and symbols follow the
HGNC nomenclature employed by EntrezGene.
Quantitative real-time PCR (QPCR)
RNA from a separate dissection of aPFC cortical tissue from all
drug abuse and control cases was DNase-treated (Qiagen Inc.,
Valencia, CA) and evaluated using the Bioanalyzer. As previously
described [14], RNA was reverse transcribed using AMV reverse
transcriptase (Roche Molecular Biologicals, Indianapolis, IN). A
commercial 18S RNA primer kit (Ambion, Austin, TX) was used
to quantify the amount of cDNA examined. Primers were
designed using MacVector software (Accelrys, San Diego, CA),
and synthesized by Gene Probe Technology (Gaithersburg, MD):
APOL2(F): aac cgc cac gat aaa gac cag; APOL2(B): cac cca caa act
cct tca tca cc; CALM2(F): gca gaa tcc cac aga agc aga g,
CALM2(B): gcc att gcc atc ctt atc aaa; SEMA3B(F): aga ctt tca gcc
tgg agc gaa c, SEMA3B(B): gca aat ggg tgc ggt tgt ag.
QPCR was performed using the DyNAmoH HotStart SYBR
Green QPCR kit and the Opticon DNA Engine (MJ Research,
Waltham, MA), using 15 min pre-incubation and 40 cycles of
denaturation at 95uC, annealing at 60uC, and extension at 72uC
(each for 30 seconds). Only data within the linear range of the
assay were used. A single product of the expected size was
confirmed by melting curve analysis and gel electrophoresis.
Individual samples were selected based on p-values. The ratio
between individual drug abuse cases and their four best-matched
controls were calculated for both QPCR experiments and for
microarray data. For the latter data, fold changes were calculated
from data scaled to the same average hybridization intensity. The
data represents an average of three independent experiments. The
limiting factor in the number of transcripts and individuals
examined was the amount of control cDNA available.
RESULTS
Groups defined by hierarchical clustering of global
transcriptional profiles
Hierarchical clustering is a natural first step in microarray analysis,
where it enables a global view of complex microarray data. This
information on the overall similarities and differences in gene
expression reveals intrinsic groupings with similarities in tran-
scriptional profiles. For human postmortem cases, which rely
heavily on anecdotal information from next-of-kin, the medical
and drug abuse history may not be fully known or disclosed, which
may significantly influence the transcriptional profile, and
hierarchical clustering thus provides an additional quality control
prior to a full comparative analysis.
In the present study, hierarchical clustering of microarray z-
ratio data identified three main transcriptional groups (Fig. 1).
Eight drug abuse (DA) cases (DA35–DA42, Group 3) were
discriminated at the first tier, suggesting that these cases were
distinctly different from the remaining 34 cases, which separated
into Group I (DA1–DA18), and Group II (DA19–DA34).
Juxtaposing drug abuse history and toxicology for each case
with the clustering dendrogram did not clearly distinguish groups
by differences in lifetime drug abuse history or by the nature of
drugs present at death (Fig. 1). A clear distinctions between
‘‘cocaine’’, ‘‘cannabis’’ and ‘‘phencyclidine’’ cases may not even
have been possible by global transcriptional profiling, as
a significant polysubstance abuse, mostly of cocaine, cannabis
and/or phencyclidine, was uncovered in the drug abuse history
and toxicological examination. Subgroups within Groups I–III
did, however, appear somewhat related to drug abuse history or
toxicology, as illustrated by a clustering of six cases with a cocaine/
crack-cocaine abuse history (DA2–7), and of two cases with similar
blood alcohol levels (DA12–13).
Overall, a past or present abuse of cocaine was indicated by the
drug abuse history and/or general and hair toxicology for a large
proportion (32/42, 76%) of the cases (Fig. 1, Table 2, Table S1).
Significant blood alcohol levels ($0.05 g/dL (g%)) were more
prominent in Group I (9/18, 50%) than in Group II cases (3/16,
19%). Conversely, opioids were not found in Group I cases, but
were present in 5/16 (31%) Group II cases. Furthermore, Group
II contained 5/9 (56%) of the phencyclidine cases, while Group I
and Group II each had two cases (22%).
Group III cases appeared different from Group I and Group II
cases, in that they represented cases with no or only residual
cocaine, cannabis or phencyclidine and metabolites, presented
with significant other medical circumstances, such as anaphylactic
shock, major depression, suicide completion, and organic disease
related to chronic alcoholism. Five cases (DA36, DA38–41) were
primarily described as alcohol dependent. The three remaining
cases (DA35, DA37, DA42) were characterized as cannabis users
by history, but general toxicology and hair testing found additional
substances, while neuropathological examination revealed cerebral
ischemic changes and/or brain edema.
Distribution of individual changes in groups defined
by global transcriptional profiles
The distinct differences in Group III compared to Groups I and II
described above were further confirmed by examination of changes
in individual transcripts for these groups (Fig. 2A). Group average
p-value (GAP) criteria, based on a two-tailed z-test comparing
z-scores for each drug abuse case to the four individually best-
matched controls, was employed to identify individual transcripts
for which expression was either increased or decreased in at least
one of the groups identified by hierarchical clustering above.
Of 808 individual transcripts identified (Fig. 2A), 89 were
significantly changed in all three groups. All were regulated in the
same direction for Groups I–II, but in the opposite direction for
Group III. Expression of 85 transcripts, including APOL2, GCC1,
PTGES, were increased for Groups I–II and decreased for Group
III. TYMS, C5orf3, PTRF and KLF5 were decreased in Groups
I–II and increased in Group III.
An additional 113 transcripts were significantly changed in
Groups I–II only; 44 transcripts, including FIBP, VTN, STOM,
ICAM1, SEMA3B, RARG, RARA, were increased, and 68
transcripts, including APOL1, CALM1, CALM2, CAMK2B,
GNB2L1, HINT1, RAB9A, CHEK1, PPP2CA and NFKBIA,
were decreased. Only one transcript, SP100, was increased in
Group I and decreased in Group II. Consequently, 201 of the 202
transcripts significantly changed in Groups I and II were changed
in the same direction.
In conclusion, compared to Groups I–II, the eight Group III cases
represented different medical and lifetime drug use histories and
toxicological profiles (Fig. 1). While the exact nature of these differ-
ences could not be causally linked to specific ante or postmortem
factors, alcohol dependence appeared to be a primary diagnosis
for 5/8 Group III cases, which along with no or low concentra-
tions of cocaine, cannabis or phencyclidine and significant other
medical problems may have led to opposite regulation in Group
III of the 89 transcripts shared among all three groups, of 91/115
transcripts changed in both Group I and Group III, and of 79/81
transcripts changed in both Groups II and III.
As Group III cases represented a small minority with distinctly
different features, we focused the study on the 34 Group I and II
cases.
Gene Expression in Drug Abuse
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toxicology and drug use history
To identify transcripts that were similarly regulated by cocaine,
cannabis and phencyclidine, we again employed GAP scores to
examine 24 Group I–II cases with a confirmed drug abuse history
and toxicological evidence of cocaine, cannabis or phencyclidine
(COC+,T H C + and PCP+, respectively) present at death. This
identified 160 transcripts shared between the COC+,T H C + and
PCP+ groups (Fig. 2B). Additionally, 474 transcripts were shared by
the COC+ and PCP+ groups, 83 transcripts by the COC+ and
THC+ groups, and 146 transcripts by the PCP+ and THC+ groups.
A total of 964, 299 and 1152 transcripts were exclusively changed in
the COC+,T H C + and PCP+ groups, respectively. The lower total
number of transcripts identified for cannabis cases was noteworthy.
In conclusion, while there were significant differences in tran-
scriptional regulation between cocaine, cannabis or phencyclidine
abuse cases, a similar transcriptional regulation extended across
drug classes and cases for 160 transcripts.
Selection and functional annotation of transcripts
shared across specific drugs of abuse
To select transcripts that would reflect effects of drug use
irrespective of which specific drug(s) were used, only transcripts
that by GAP criteria were significantly changed in the majority
(30/34) of Group I–II drug abuse cases and in two of the three
drug-defined groups (COC+, THC+, and PCP+) were included.
After exclusion of cDNA clones removed from GenBank, the list
contained 139 transcripts, which were sorted according to function
and location (Table S2). Three functional groups, comprising 39
transcripts (Table 3), are discussed below.
Calmodulin-related signaling
A general decrease was observed for calcium/calmodulin-
regulated transcripts (CALM1, CALM2, CAMK2B, S100A16)
and a transcript encoding a phosphatase putatively involved in
cAMP biosynthesis and adenylate cyclase (AC) activity (THTPA).
Golgi/ER-related transcripts
Transcripts involved in various aspects of Golgi/ER function
(YIPF5, GCC1, COG4, COPZ1, VPS37C, LEPREL1, CPVL,
SEMA3B) were increased. Also increased were transcripts
encoding adaptins and an adaptin kinase (AP1M2, AP2A1,
AP4B1, AAK1) associated with clathrin-coated vesicle endocytosis
at the plasma membrane and in transport between the Golgi
apparatus and the endosomal system. While transcripts encoding
lysosomal enzymes (CTSD, DPP7) were increased, transcripts
encoding proteins involved in synaptic vesicular trafficking
(RIMBP2, ARL6IP4), transport from the late endosome to the
lysosome (ASGR2, RAB9A), and a marker of cholesterol- and
sphingolipid-rich lipid raft membrane microdomains involved in
clathrin-independent endocytosis (FLOT1) were all decreased.
Lipid/cholesterol metabolism
Most transcripts regulating cholesterol biosynthesis (FDFT1,
PRKAB1) and trafficking (SCARB1, APOL2) were increased,
Figure 2. Venn Diagrams illustrating the distribution of significantly altered transcripts in groups defined by global expression profiles (A) or by drugs of
abuse (B).
A. Eighty-nine transcripts were regulated in all three groups defined by global expression profiles. All of these were regulated in the same direction
(increased or decreased) for Group I (DA1–18) and Group II (DA19–34), and in the opposite direction for Group III (DA35–42) cases. In all, 201/202
transcripts shared between Group I and Group II were regulated in the same direction. For Group III, 91/115 transcripts shared with Group I and 79/81
transcripts shared with Group II were regulated in the opposite direction. These data highlight the similarities of Group I and Group II, and the marked
differences in Group III cases. Each cluster of three arrows indicates the direction of change in Groups I, II and III, respectively. Increased expression is
indicated by q, a decrease by Q, while R indicates no significant change.
B. Cases with a drug abuse history and positive cocaine, phencyclidine or cannabinoid toxicology in blood, brain or urine were grouped into COC+,
PCP+ and THC+ groups, respectively. While there were significant transcriptional differences between these groups, a total of 160 transcripts (<2% of
all transcripts) were shared for the three groups. Note that a much smaller number of transcripts were identified for the THC+ group (264 increased,
424 decreased) than for the COC+ (982 increased, 699 decreased) and PCP+ (911 increased, 1021 decreased) groups. Increased expression is indicated
by q, decreased expression by Q.
doi:10.1371/journal.pone.0000114.g002
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a peroxisomal protein (ECHDC1) involved in beta-oxidation of
cholesterol were decreased. Expression of the LASS4, PTGES,
ZDHHC1 and ZDHHC8 transcripts involved in lipid biosynthe-
sis, metabolism and modification were all increased.
Quantitative Polymerase Chain Reaction (QPCR)
Transcripts representing three consistently changed functional
classes were examined using QPCR (Fig. 3). These experiments
were performed in triplicate for each drug abuse case and their
individual four best-matched controls, using different aPFC
dissections and RNA extractions than those used for microarray
experiments. Microarray data were expressed as fold changes
between individual drug abuse and control cases to facilitate
a more direct comparison to similar ratio data from QPCR
analysis of the same drug abuse and control cases.
Calmodulin 2 (CALM2) expression (Fig. 3, blue bars) was
decreased in two microarray CALM2 clones. QPCR validated
decreased CALM2 expression in 7 of 9 drug abuse cases.
Apolipoprotein L, 2 (APOL2) expression (Fig. 3, green bars) was
increased by microarray analysis. QPCR validated the increase in
13 of 17 cases. To examine if decreases detected by microarray
analysis were demonstrable by QPCR, one Group III case, DA38,
was employed. The decreased expression for this case was
validated.
Semaphorin 3B (SEMA3B) expression (Fig. 3, orange bars) was
increased by microarray analysis, which was validated in 11 of 11
cases examined by QPCR.
While some variability was expected, given that separate
dissections were employed for microarray analysis and QPCR
experiments, the general pattern and degree of difference detected
by the two techniques were very similar, and results agreed in 32/
38 cases (84%).
Specificity of these findings with respect to ethnicity
While there was similar matching of the drug abuse and control
groups for five (brain pH, PMI, age, gender and smoking history) potential
confounding factors (Table 1), a sixth matching factor (ethnicity)
differed, and a separate analysis was performed to address this.
As 36 of the drug abuse cases were African-American (86%) and
most were male (33/42, 79%), we examined the average statistical
significance of differences (Group average p-value, GAP, two-
tailed z-test) between drug abuse and control cases for the six drug
abuse cases for which both drug abuse and all four control cases
were male and of African-American origin (AAM). Even though
this analysis employed only ,1/6 of the 34 drug abuse cases
analyzed (Table 3), 37 of 39 transcripts analyzed remained
significant at a similar level. For NCLN, the average p-value was
0.22, due to one outlier, but the median was 0.00 for the six AAM
cases, indicating that this transcript was similarly changed for most
of the cases. For PRKAB1, the average p-value decreased from
p=0.91 for all 34 cases to p=0.30 for the six AAM drug abuse
cases (median p=0.03). Thus, 38 of 39 transcripts were similarly
changed when comparing all cases to the six AAM drug abuse
cases. Therefore, the ethnicity of the cases did not exert a major
influence on the identification of significantly changed transcripts
across drug abuse cases.
Specificity of these findings to drug abuse
In order to determine whether these changes were specific to drug
abuse or might reflect a common physiological response to
cardiovascular disease, as common complication in drug abuse
cases, or oxidative stress secondary to drug abuse, we examined
control cases with or without cardiovascular disease. Six over-
weight-obese control cases with cardiovascular disease and six
normal-overweight control cases with no history of cardiovascular
disease were compared. GAP scores did not reach significance for
any of transcripts identified to be increased or deceased in drug
abuse cases (Table 3, Table S2).
DISCUSSION
The prefrontal cortex is centrally involved in the neurobiological
circuitry that promotes drug use and compulsive drug-seeking
behavior, and appears to be similarly involved for various drugs of
abuse [3,4]. We therefore hypothesized that multiple types of drug
abuse would share common transcriptional changes, due to similar
changes in cellular function. We tested this using microarray
analysis of postmortem aPFC from 42 cases with varied drug
abuse histories as determined by postmortem case history reviews,
next-of-kin interviews, and toxicological examination.
Global transcriptional changes
Hierarchical clustering of the global transcriptional profiles and
examination of changes in individual transcripts demonstrated
consistent changes in gene expression in a majority of cases
(N=34). A subgroup of eight drug abuse cases displayed markedly
different, and mostly opposite, gene expression changes which
appeared to reflect distinct differences in lifetime drug abuse
histories, toxicology and other medical conditions.
Functional annotation
Based on the cohort of 34 drug abuse cases, we identified and
assigned function and/or location to 139 transcripts (Table S2).
None of these transcripts were significantly altered by the
combined cellular stress of cardiovascular disease and elevated
body mass index (Table 3, Table S2). Three distinct functional
categories (Table 3) were selected for further discussion in the
context of their potential impact on aPFC function.
Calmodulin signaling
Transcripts encoding calcium/calmodulin-related signaling tran-
scripts were decreased, which was validated for CALM2 by QPCR
(Fig. 3). Studies in human postmortem brain have previously
demonstrated a general decrease in calcium/cAMP-related
signaling transcripts in frontal and motor cortex of human
alcoholics [13], a decrease in adenylate cyclase (AC) type I (AC-
I) protein levels and activity in temporal and frontal cortex in
alcoholics [22–23] and in AC-I mRNA and protein in temporal
cortex from heroin addicts [24]. While AC-I protein levels were
unchanged in prefrontal cortex from opiate addicts, there were
significant decreases in the downstream MAPK signaling cascade
[25]. Furthermore, methamphetamine administration decreased
calcium/calmodulin-dependent protein kinase II (CAMKII)
activity and phosphorylated (but not total) CAMKIIa in rat
frontal and parietal cortex [26].
Since calmodulin has been hypothesized to be a central
integrator of synaptic plasticity [27] and modulates the activity
and calcium-sensitivity of key signaling molecules, such as AC,
CAMKII and IV (CAMKIV), and the Ras-MAPK signaling
pathway, this effect could significantly impact a number of
downstream signaling pathways. One such target is CAMKII,
which is critical for the establishment of synaptic plasticity and
memory and in stabilizing dendritic architecture [28], with
a specific role for CAMKIIB in targeting the alpha CAMKII
isoform to dendritic spines and the cell cortex [29]. The significant
decrease in CALM1, CALM2 and CAMKIIB transcripts suggest
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by calmodulin-regulated pathways could be a common theme in
human abuse of cocaine, cannabis and/or phencyclidine.
Lipid and cholesterol metabolism: Apolipoprotein L
family
Increased transcription was demonstrated for transcripts related to
lipid and cholesterol metabolism, except for two transcripts
encoding proteins that reduce available cholesterol in the cell by
excretion or metabolism. Expression of transcripts encoding the first
specific step in the cholesterol biosynthetic pathway (FDFT1), the
high-density lipoprotein (HDL) receptor (SCARB1) and an in-
hibitor of cholesterol biosynthesis (PRKAB1) were increased. Of
particular note were increases in the apoliprotein L (APOL)
transcripts, for which the increased expression of APOL2 was
validatedbyQPCR(Fig.3).APOLfamilyproteinsareHDLs,which
play a central role in cholesterol transport and homeostasis. The six
known APOL genes are exclusively present in primates, with the
APOL1-4 genes forming a tight cluster on human chromosome
22q13.1 [30]. The APOL2 transcript is most highly expressed in
brain, while the APOL1 transcript differs from other APOL
transcripts by an additional exon that produces a secreted APOL
protein [30]. These differences may also underlie the opposite
changes in the APOL1 and APOL2 transcripts in the drug abuse
cases. APOL4 was significantly increased only in the cocaine cases.
Cholesterol is indispensable for neuronal functioning, synaptic
plasticity and CNS myelination [31–32]. Functionally, this may
also relate to the decreased frontal white matter volume observed
in drug abusers [33]. Normal white matter maturation appears to
be arrested in the frontal and temporal lobes in cocaine abusers
[34]. Microarray studies have demonstrated changes in myelin
transcripts in the nucleus accumbens and prefrontal cortex of
cocaine abusers [14,16]. This is reminiscent of the situation in the
prefrontal cortex in schizophrenia, where expression of APOL1, 2
and 4 transcripts were increased [35], and myelin transcripts were
decreased [9]. Importantly, changes in these primate-specific lipid
metabolism genes underscore inherent differences between non-
primate models and human drug abuse at a cellular level, and
highlight the importance of studies in human postmortem brain.
Figure 3. Validation of microarray data by quantitative PCR (QPCR).
Three representatives of consistently changed functional groups (Table 3) were examined by QPCR: calmodulin 2 (CALM2, blue bars), apolipoprotein
2 (APOL2, green bars), and semaphorin 3B (SEMA3B, orange bars). Numbers on the x-axis represents either the microarray-derived fold change (FC,
lighter blue, green or orange bars) for each drug abuse case compared to the four best-matched control cases or the QPCR ratio (QPCR, darker blue,
green or orange bars), while numbers on the y-axis represent the drug abuse case examined. QPCR validated 32/38 (84%) of the microarray data,
which was performed using separate sets of brain dissections and RNA extractions from each drug abuse case and the four individual best-matched
controls.
doi:10.1371/journal.pone.0000114.g003
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compartments
A number of transcripts encoding proteins regulating intracellular
trafficking of secretory pathways were changed, with a predomi-
nant increase in transcription of ER/Golgi-related transcripts.
Increased transcription of the ER-resident protein semaphorin 3B
(SEMA3B) was validated by QPCR (Fig. 3). This increase mirrors
the significant cocaine-induced increases of SEMA3B mRNA in
the hippocampus and nucleus accumbens of cocaine-sensitized or
chronically cocaine-treated animals [36]. Secreted semaphorins
play critical roles in growth cone guidance, axonal positioning and
in modulating apical cortical dendrites [37–39], dendritic branch-
ing and spine maturation [39] and may modulate synaptic
transmission in the adult brain [40]. Transcription of clathrin
adaptors and an adaptor-associated kinase functioning in clathrin-
coated carrier vesicles between the trans-Golgi network and the
endosomal system, and endocytic vesicles at the plasma membrane
were also consistently increased. Transcripts for which expression
was decreased were mainly associated with synaptic vesicular
trafficking, clathrin-independent endocytosis or transport from the
late endosome to the lysosome.
Neurons have a unique organization of their secretory pathway,
with membrane and lipid processing in somatic Golgi, and
additional ER-to-Golgi transport in dendrites [41], which enables
dendrites with Golgi to be longer and more complex [42]. In that
context, the shared increases in transcription of genes relating to
ER and Golgi synthesis and processing, and decreased transcrip-
tion of genes invested in other transport functions is interesting,
and suggests that changes in aPFC dendritic function and plasticity
is shared among drug abuse cases.
Implications
It has been established that drugs of abuse such as cocaine,
amphetamine and morphine impart an experience-dependent
structural plasticity that alters dendritic length and complexity in
brain areas associated with persistent drug-induced changes [43–
45], changes which may additionally limit later experience-
dependent structural plasticity [46].
The aPFC is distinguished from other cortical regions by its
highly complex synaptic connectivity and dendritic arborization
[5–6]. Therefore, the specific changes in transcripts involved in
calmodulin-regulated signaling, cholesterol metabolism and ER/
Golgi function may be correlates of drug-induced changes in
neuronal function and synaptic plasticity that are shared by
cocaine, cannabis and phencyclidine abuse.
SUPPORTING INFORMATION
Table S1 Essential demographic data for the drug abuse. Each
drug abuse case was matched to four controls as indicated in the
control group column by brain pH, postmortem interval (PMI,
hours), age (years), ethnicity (A - Asian, AA - African-American,
CAUC - Caucasian, HISP - Hispanic), gender (F - female, M -
male) and smoking history (YES or NO). Manner of death was
accidental (A), natural (N), a homicide (H) or suicide (S). Control
cases with CVD (CTR12, 23, 27, 30–32) were compared to
control cases without CVD (CTR5, 7, 10, 11, 14, 26), as indicated
in italics in the control group column, to examine the effect of
cardiovascular disease on gene expression. Other abbreviations:
ASCVD - atherosclerotic CVD, CVD - cardiovascular disease,
GSW - Gunshot wound, HCVD - hypertensive CVD, MGSW -
multiple GSWsst of transcripts. Gene symbols were annotated
using GenBank Accession numbers and EntrezGene.
Found at: doi:10.1371/journal.pone.0000114.s001 (0.04 MB
DOC)
Table S2 Full list of significantly regulated transcripts in
postmortem aPFC from cocaine, phencyclidine and/or cannabis
abusers. One-hundred and thirty-nine transcripts were significant-
ly regulated by group average p-value (GAP) criteria. Overweight/
obese controls with cardiovascular disease (CVDC) compared to
normal/overweight controls (Table S1) illustrated that drug-
induced cellular stress was not an underlying cause in the common
transcriptional patterns in the drug abuse cases. Gene symbols
were annotated using GenBank Accession numbers and Entrez-
Gene.
Found at: doi:10.1371/journal.pone.0000114.s002 (0.06 MB
DOC)
ACKNOWLEDGMENTS
The authors gratefully acknowledge the families of the individuals studied,
the Offices of the Chief Medical Examiner of the District of Columbia and
of Northern Virginia, Dr. Mary Herman and Ms. Vesna Imamovic,
CBDB, GCAP, NIMH IRP, and Mr. William H. Wood, GEGU, RRB,
NIA IRP.
Author Contributions
Conceived and designed the experiments: EL WF. Performed the
experiments: EL CC AD RL TH JK. Analyzed the data: EL AD RL
MH. Contributed reagents/materials/analysis tools: KB RL MH TH JK.
Wrote the paper: EL WF.
REFERENCES
1. Rounsaville BJ, Petry NM, Carroll KM (2003) Single versus multiple drug
focus in substance abuse clinical trials research. Drug Alcohol Depend 70:
117–125.
2. Nestler EJ (2005) Is there a common molecular pathway for addiction? Nat
Neurosci 8: 1445–1449.
3. Goldstein RZ, Volkow ND (2002) Drug addiction and its underlying
neurobiological basis: neuroimaging evidence for the involvement of the frontal
cortex. Am J Psychiatry 159: 1642–1652.
4. Spinella M (2003) Relationship between drug use and prefrontal-associated
traits. Addict Biol 8: 67–74.
5. Jacobs B, Schall M, Prather M, Kapler E, Driscoll L, et al. (2001) Regional
dendritic and spine variation in human cerebral cortex: a quantitative Golgi
study. Cereb Cortex 11: 558–571.
6. Ramnani N, Owen AM (2004) Anterior prefrontal cortex: insights into function
from anatomy and neuroimaging. Nat Rev Neurosci 5: 184–194.
7. Kufahl PR, Li Z, Risinger RC, Rainey CJ, Wu G, et al. (2005) Neural responses
to acute cocaine administration in the human brain detected by fMRI.
NeuroImage 28: 904–914.
8. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000) Molecular
characterization of schizophrenia viewed by microarray analysis of gene
expression in prefrontal cortex. Neuron 28: 53–67.
9. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, et al. (2001) Genome-wide
expression analysis reveals dysregulation of myelination-related genes in chronic
schizophrenia. Proc Natl Acad Sci U S A 98: 4746–4751.
10. Sokolov BP, Jiang L, Trivedi NS, Aston C (2003) Transcription profiling reveals
mitochondrial, ubiquitin and signaling systems abnormalities in postmortem
brains from subjects with a history of alcohol abuse or dependence. J Neurosci
Res 72: 756–767.
11. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, et al. (2002)
Microarray analysis of gene expression in the prefrontal cortex in schizophrenia:
a preliminary study. Schizophrenia Res 58: 11–20.
12. Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, et al. (2004) Proc Natl
Acad Sci U S A 101: 15506–15511.
13. Mayfield RD, Lewohl JM, Dodd PR, Herlihy A, Liu J, et al. (2002) Patterns of
gene expression are altered in the frontal and motor cortices of human
alcoholics. J Neurochem 81: 802–813.
Gene Expression in Drug Abuse
PLoS ONE | www.plosone.org 10 December 2006 | Issue 1 | e11414. Lehrmann E, Oyler J, Vawter MP, Hyde TM, Kolachana B, et al. (2003)
Transcriptional profiling in the human prefrontal cortex: evidence for two
activational states associated with cocaine abuse. Pharmacogenomics J 3: 27–40.
15. Tang WX, Fasulo WH, Mash DC, Hemby SE (2003) Molecular profiling of
midbrain dopamine regions in cocaine overdose victims. Molecular profiling of
midbrain dopamine regions in cocaine overdose victims. J Neurochem 85:
911–924.
16. Albertson DN, Pruetz B, Schmidt CJ, Kuhn DM, Kapatos G, et al. (2004) Gene
expression profile of the nucleus accumbens of human cocaine abusers: evidence
for dysregulation of myelin. J Neurochem 88: 1211–1219.
17. Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE (2006)
Critical factors in gene expression in postmortem human brain: focus on studies
in schizophrenia. Biol Psychiatry 60: 650–658.
18. Lowe RH, Barnes AJ, Lehrmann E, Freed WJ, Kleinman JE, et al. (2006) A
validated positive chemical ionization GC/MS method for the identification and
quantification of amphetamine, opiates, cocaine, and metabolites in human
postmortem brain. J Mass Spectrom 41: 175–184.
19. Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, et al. (2002)
Generation and initial analysis of more than 15,000 full-length human and
mouse cDNA sequences. Proc Natl Acad Sci U S A 99: 16899–16903.
20. Cheadle C, Vawter MP, Freed WJ, Becker KG (2002) Analysis of microarray
data using Z score transformation. J Mol Diagn 5: 73–81.
21. Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of
microarray data. Bioinformatics 18: 207–208.
22. Sohma H, Hashimoto E, Shirasaka T, Tsunematsu R, Ozawa H, et al. (1999)
Biochim Biophys Acta 1454: 11–18.
23. Hashimoto E, Frolich L, Ozawa H, Saito T, Maurer K, et al. (1998) Reduced
immunoreactivity of type I adenylyl cyclase in the postmortem brains of
alcoholics. Alcohol Clin Exp Res 22: 88S–92S.
24. Shichinohe S, Ozawa H, Hashimoto E, Tatschner T, Riederer P, et al. (2001)
Changes in the cAMP-related signal transduction mechanism in postmortem
human brains of heroin addicts. J Neural Transm 108: 335–347.
25. Ferrer-Alco ´n MJ, Garcia-Fuster M, La Harpe R, Garcia-Sevilla JA (2004) Long-
term regulation of signalling components of adenylyl cyclase and mitogen-
activated protein kinase in the pre-frontal cortex of human opiate addicts.
J Neurochem 90: 220–230.
26. Suemaru J, Akiyama K, Tanabe Y, Kuroda S (2000) Methamphetamine
decreases calcium-calmodulin dependent protein kinase II activity in discrete rat
brain regions. Synapse 36: 155–166.
27. Xia Z, Storm DR (2005) The role of calmodulin as a signal integrator for
synaptic plasticity. Nat Rev Neurosci 6: 267–276.
28. Merrill MA, Chen Y, Strack S, Hell JW (2005) Activity-driven postsynaptic
translocation of CaMKII. Trends Pharmacol Sci 26: 645–653.
29. Shen K, Terual MN, Subramanian K, Meyer T (1998) CaMKIIbeta functions
as an F-actin targeting module that localizes CaMKIIalpha/beta heterooligo-
mers to dendritic spines. Neuron 21: 593–606.
30. Monajemi H, Fontijn RD, Pannekoek H, Horrevoets AJ (2002) The
apolipoprotein L gene cluster has emerged recently in evolution and is
expressed in human vascular tissue. Genomics 79: 539–546.
31. Pfrieger FW (2003) Cholesterol homeostasis and function in neurons of the
central nervous system. Biochim Biophys Acta 1610: 271–280.
32. Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, et al. (2005) High
cholesterol level is essential for myelin membrane growth. Nat Neurosci 8:
468–475.
33. Schlaepfer TE, Lancaster E, Heidbreder R, Strain EC, Kosel M, et al. (2005)
Decreased frontal white-matter volume in chronic substance abuse.
Int J Neuropsychopharmacol 8: 1–7.
34. Bartzokis G, Beckson M, Lu PH, Edwards N, Bridge P, et al. (2002) Brain
maturation may be arrested in chronic cocaine addicts. Biol Psychiatry 51:
605–611.
35. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, et al. (2002) Gene
expression analysis in schizophrenia: reproducible up-regulation of several
members of the apolipoprotein L family located in a high-susceptibility locus for
schizophrenia on chromosome 22. Proc Natl Acad Sci U S A 99: 4680–4685.
36. Bahi A, Dreyer JL (2005) Cocaine-induced expression changes of axon guidance
molecules in the adult rat brain. Mol Cell Neurosci 28: 275–291.
37. Falk J, Bechara A, Fiore R, Nawabi H, Zhou H, et al. (2005) Dual functional
activity of semaphorin 3B is required for positioning the anterior commissure.
Neuron 48: 63–75.
38. Polleux F, Morrow T, Ghosh A (2000) Semaphorin 3A is a chemoattractant for
cortical apical dendrites. Nature 404: 567–573.
39. Morita A, Yamashita N, Sasaki Y, Uchida Y, Nakajima O, et al. (2006)
Regulation of dendritic branching and spine maturation by semaphorin3A-Fyn
signaling. J Neurosci 26: 2971–2980.
40. Sahay A, Kim CH, Sepkuty JP, Cho E, Huganir RL, et al. (2005) Secreted
semaphorins modulate synaptic transmission in the adult hippocampus.
J Neurosci 25: 3613–620.
41. Horton AC, Ehlers MD (2003) Dual modes of endoplasmic reticulum-to-Golgi
transport in dendrites revealed by live-cell imaging. J Neurosci 23: 6188–6199.
42. Horton AC, Racz B, Monson EE, Lin AL, Weinberg RJ, et al. (2005) Polarized
secretory trafficking directs cargo for asymmetric dendrite growth and
morphogenesis. Neuron 48: 757–771.
43. Robinson TE, Gorny G, Mitton E, Kolb B (2001) Cocaine self-administration
alters the morphology of dendrites and dendritic spines in the nucleus
accumbens and neocortex. Synapse 39: 257–266.
44. Robinson TE, Gorny G, Savage VR, Kolb B (2002) Widespread but regionally
specific effects of experimenter- versus self-administered morphine on dendritic
spines in the nucleus accumbens, hippocampus, and neocortex of adult rats.
Synapse 46: 271–279.
45. Crombag HS, Gorny G, Li Y, Kolb B, Robinson TE (2005) Opposite effects of
amphetamine self-administration experience on dendritic spines in the medial
and orbital prefrontal cortex. Cereb Cortex 15: 341–348.
46. Kolb B, Gorny G, Li Y, Samaha AN, Robinson TE (2003) Amphetamine or
cocaine limits the ability of later experience to promote structural plasticity in the
neocortex and nucleus accumbens. Proc Natl Acad Sci U S A 100:
10523–10528.
Gene Expression in Drug Abuse
PLoS ONE | www.plosone.org 11 December 2006 | Issue 1 | e114